Skip to main content

Main menu

  • About Us
    • Leadership
    • Our Team
    • Vision, Mission and Values
    • Health and Economic Impact
    • Research Impact Video
    • Strategic Plan
  • Our Research
    • Research Focus
      • Brain Health
      • Cancer
      • Digital Health and Artificial Intelligence
      • Heart Health
      • Healthy Aging and Mobility
      • Immune System
      • Injury and Rehabilitation
      • Lung Health
      • Mental Health and Substance Use
    • Research Centres and Programs
      • BC Centre on Substance Use
      • Centre for Aging SMART
      • Centre for Cardiovascular Innovation
      • Centre for Clinical Epidemiology and Evaluation
      • Centre for Lung Health
      • Djavad Mowafaghian Centre for Brain Health
      • Immunity and Infection Research Centre
      • International Collaboration On Repair Discoveries
      • M. H. Mohseni Institute of Urologic Sciences
      • Ovarian Cancer Research Centre
      • Community Research Program
      • Emergency Medicine Research Program
      • Hematology Research Program
      • Skin Research Program
      • Other Research Focus Areas
    • News and Stories
    • Researcher Directory
    • Events and Workshops
  • Research Services
    • New to VCHRI
      • Working at VCHRI
      • Regulations and Training
      • Membership with VCHRI
      • Learning and Development
    • Starting Your Project
      • Research Facilitation
      • Awards and Funding
      • Grant Management
      • Operational Approval
      • CST Cerner
    • Developing Your Project
      • Clinical Trials Administration
      • Clinical Research Unit
      • Research Privacy
      • Financial Policies and Procedures
    • Additional Support
      • Indigenous Health Research Unit
      • VCH-VCHRI AI Hub
      • Communications and Media Relations
      • Study Recruitment Support
      • Innovation and Industry Partnership
    • Internal Awards
    • Clinical Research
    • Indigenous Research
  • Participate in Research
    • Reasons to Participate
    • Participant Stories
    • Find a Study
    • Recruitment Support

User menu

  • Log in

Breadcrumb

  1. Home
  2. Our Research
  3. News and Stories
  4. How now, green cow?

How now, green cow?

Stories Dec 1, 2014 2 minutes

Naturally occurring nitric oxide defends against rampant beef cattle disease.

Canadians love their beef. In 2012, Canadians consumed an average of 44.1 lbs of beef per person yearly1. The greatest challenge to mass producing beef in order to meet this demand is Bovine Respiratory Disease Complex (BRDc) – a multi-factorial disease that accounts for 75% of the morbidity and more than 50% of the mortality in feedlot cattle and requires broad use of antibiotics.

A novel nitric oxide (NO)-releasing solution intranasal spray developed by Vancouver Coastal Health Research Institute scientist Dr. Chris Miller is presenting Canada’s beef cattle industry with the opportunity to continue mass production and reduce the prevalence of BRDc without the use of medication.

“The industry wants to move towards alternatives to antibiotics in preventing and treating BRDc and nitric oxide may be the answer – it’s the body’s first defense,” explains Dr. Miller, scientist at the Immunity and Infection Research Centre and Assistant Professor at the UBC Faculty of Medicine, Respiratory Division. 

NO is a naturally occurring cellular molecule in most mammals, and possesses a wide variety of biochemical characteristics. Studies have shown it to be an effective antimicrobial agent against a broad range of microorganisms, including multi-drug resistant strains of bacteria and viruses.

Dr. Miller has been researching NO since 1990 and wrote the first review article of NO in 1992. Through their company Bovicor Pharmatech Inc., Dr. Miller and the team have developed the first NO-nitrosylite as an intranasal NO-releasing spray called BovinexTM that can be administered in a few seconds to beef cattle during processing at the feedlot. 

Their first study of BovinexTM given to beef cattle showed that, in comparison to a placebo, incidence of BRDc in cattle arriving in the feedlot was reduced from 72 per cent to 28 per cent.

In fall of 2013, the team completed a study (in the process of being published in a peer review periodical) of 1,080 feedlot animals in in Alberta and found that the spray was as effective against BRDc as antibiotics. A subsequent study has also shown that the NO administered to the cattle leaves no residue or trace in the beef ready for consumption.

BovinexTM has been presented to the U.S. Food and Drug Administration and Health Canada and is going through the approval process to be the first NO-based therapy for prophylactic use in cattle. 

“Our hope is that 90% of the animals will be antibiotic free,” says Dr. Miller. “My dream is to see this being used in all animals in B.C. This could give us ‘green’ antibiotic-free B.C. beef.”

 

1 Canada's Beef Industry Fast Facts 2013 

 

Share:

  • Facebook
  • Linkedin
  • Twitter
  • Email

Related Research Centres/Programs

Immunity and Infection Research Centre

Get the latest research headlines in your inbox

Subscribe

Recent News and Stories

Type
Announcement

Investigator Awards 2025 Recipients

Apr 29, 2025 award
Type
Stories

Ask an expert: What should I know about kidney stones?

Apr 23, 2025 kidney, treatment options
Type
Stories

New solution to treat obstructive sleep apnea

Apr 22, 2025 sleep, treatment options
See more news

Get updates!

Join our newsletter mailing list to stay up to date on features and releases.

Subscribe

Quick Links

  • News and Stories
  • Careers
  • Events
  • Media Enquiries

Follow Us

  • LinkedIn
  • X
  • YouTube

© 2025 VCHRI. All rights reserved.

  • Contact
  • Privacy Policy